Massachusetts medical device maker Fractyl announced this week that it raised $40 million in support of its ablation-based approach to type 2 diabetes, which looks promising in early studies.
The company closed a Series C funding round for its Revita Duodenal Mucosal Resurfacing (DMR) technology, designed to ablate the duodenum (the first part of the intestine) in order to alter glucose metabolism. Fractyl calls its approach the "first procedural therapy to treat type 2 diabetes."
In a study of 30 patients treated with the Revita system, 19 who underwent more extensive DMR in the duodenum saw their HbA1c levels drop from an average of 9.2 prior to surgery to 7.1 after 3 months, with results sustained 6 months after the procedure, according to a Fractyl statement. Other patients who had ablation over a shorter segment of the duodenum didn’t see as much benefit.
"While early, we believe these results validate our approach and indicate the significant impact that the Revita DMR procedure could have for patients afflicted with type 2 diabetes," Fractyl CEO Dr. Harith Rajagopalan said in prepared remarks. "We are preparing to launch our multinational study by the end of the year and working towards our clinical development efforts in the U.S., which we expect to commence during 2016."
The new funding was led by Mithril, and the investment firm’s co-founder and managing general partner Ajay Royan joined Fractyl’s board of directors. Previous Fractyl funders General Catalyst, Bessemer Venture Partners and Domain Associates also participated in the round.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.